ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Short Interest Down 50.8% in December

Posted by Teresa Graham on Jan 17th, 2026

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) saw a significant decrease in short interest in December. As of December 31st, there was short interest totaling 25,624 shares, a decrease of 50.8% from the December 15th total of 52,121 shares. Based on an average daily trading volume, of 43,424 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.0% of the company’s shares are sold short. Currently, 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 43,424 shares, the days-to-cover ratio is currently 0.6 days.

ALPS Medical Breakthroughs ETF Trading Down 0.3%

Shares of NYSEARCA:SBIO traded down $0.15 during trading on Friday, reaching $51.07. 25,687 shares of the company traded hands, compared to its average volume of 51,753. ALPS Medical Breakthroughs ETF has a 1-year low of $22.33 and a 1-year high of $52.90. The firm has a fifty day simple moving average of $49.72 and a 200 day simple moving average of $41.31.

Hedge Funds Weigh In On ALPS Medical Breakthroughs ETF

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Comerica Bank acquired a new position in shares of ALPS Medical Breakthroughs ETF in the third quarter valued at about $27,000. Raymond James Financial Inc. acquired a new stake in shares of ALPS Medical Breakthroughs ETF in the second quarter valued at approximately $82,000. Ally Invest Advisors Inc. bought a new stake in shares of ALPS Medical Breakthroughs ETF in the second quarter valued at approximately $200,000. Moran Wealth Management LLC acquired a new stake in ALPS Medical Breakthroughs ETF during the second quarter worth approximately $300,000. Finally, Sterling Investment Advisors Ltd. acquired a new position in ALPS Medical Breakthroughs ETF in the 3rd quarter valued at $315,000.

About ALPS Medical Breakthroughs ETF

(Get Free Report)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.